Puretech Presents New Data From Phase 2b Open-Label Extension Study Of Deupirfenidone

PureTech Health PLC PRTC:

• PURETECH PRESENTS NEW DATA FROM PHASE 2B OPEN-LABEL EXTENSION STUDY OF DEUPIRFENIDONE (LYT-100), FURTHER SUPPORTING STRONG AND DURABLE EFFICACY AND POTENTIAL TO SERVE AS NEW STANDARD OF CARE IN IPF

• PURETECH HEALTH PLC - PATIENTS SWITCHING TO DEUPIRFENIDONE ACHIEVED LUNG FUNCTION STABILIZATION WITH FAVORABLE TOLERABILITY

• PURETECH HEALTH PLC - PHASE 3 TRIAL DESIGN UPDATE EXPECTED Q4 2025